Skip to main content

Drug Interactions between delavirdine and tiagabine

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

delavirdine tiaGABine

Applies to: delavirdine and tiagabine

Serum concentrations and effects of medications that are metabolized by the 3A4 enzymatic pathways may theoretically be elevated in patients receiving delavirdine. The mechanism is inhibition of these enzymes by delavirdine. The clinical significance is unknown. Monitoring for clinical and laboratory evidence of safety and tolerance is recommended. Dosage adjustments or alternatives may be needed if an interaction is suspected.

References (6)
  1. Cheng CL, Smith DE, Carver PL, Cox SR, Watkins PB, Blake DS, Kauffman CA, Meyer KM, Amidon GL, Stetson PL (1997) "Steady-state pharmacokinetics of delavirdine in HIV-positive patients: Effect on erythromycin breath test." Clin Pharmacol Ther, 61, p. 531-43
  2. (2001) "Product Information. Rescriptor (delavirdine)." Pharmacia and Upjohn
  3. Barry M, Mulcahy F, Merry C, Gibbons S, Back D (1999) "Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection." Clin Pharmacokinet, 36, p. 289-304
  4. Voorman RL, Maio SM, Payne NA, Zhao Z, Koeplinger KA, Wang X (1998) "Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A." J Pharmacol Exp Ther, 287, p. 381-8
  5. vonMoltke LL, Greenblatt DJ, Granda BW, Giancarlo GM, Duan SX, Daily JP, Harmatz JS, Shader RI (2001) "Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors." J Clin Pharmacol, 41, p. 85-91
  6. Fichtenbaum CJ, Gerber JG (2002) "Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection." Clin Pharmacokinet, 41, p. 1195-211

Drug and food interactions

Moderate

tiaGABine food

Applies to: tiagabine

GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

References (4)
  1. Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
  2. Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
  3. (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
  4. (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer